American Diabetes Association Names John J. Agos as New Chief Strategic Development Officer

Contact

Michelle Kirkwood
press@diabetes.org
703-299-2053

Arlington, Virginia
February 21, 2018

Accomplished healthcare executive John J. Agos has been named Chief Strategic Development Officer (CSDO) for the American Diabetes Association (ADA). Mr. Agos joined the ADA on February 12 from global health care company Sanofi, where he served as the North America Diabetes Public Affairs Lead in its Global External Affairs Division. 

As ADA’s CSDO, Mr. Agos joins the Executive Team reporting to the CEO and leads the Corporate Alliances, Grants, Major Donors, Foundations and Transformational Giving teams. His expertise in the health care industry will steward relationships and forge innovative partnerships with the many critical stakeholders necessary for the ADA to achieve its mission and solidify ADA’s leadership role in the diabetes community. Mr. Agos has been an ardent supporter of the ADA throughout his career, and the personal impact of diabetes in his own family fueled his desire to have a more integral role within ADA.

“I am pleased to welcome John to the ADA, and we look forward to the critical strategic thinking and business development skills he brings,” said ADA’s Interim CEO Martha P. Clark. “John has a long history of uniting the people, organizations, and treatments leading to solutions that transcend the traditional avenues of health care. His skills will help the ADA make an even bigger impact on improving the lives of the millions of people living with diabetes.”

During his 15 years with Sanofi, Mr. Agos served in several senior-level positions with an emphasis on patient health, advocacy partnerships, U.S. policy, business strategy and U.S. managed markets.  He built multi-stakeholder collaborations between physicians and care providers, patients and families, pharmacists, and health advocates to interconnect capabilities critical to improving patient health, resulting in solutions to chronic health issues beyond pharmaceuticals. Mr. Agos’s roles at Sanofi have included Senior Director for Partners in Patient Health and Senior Director for U.S. Policy and Strategic Advocacy. Before joining Sanofi, he led strategy development for product launches and consumer engagement as Senior Vice President and Managing Partner at QAS Consultant Group between 2002 and 2003. He also held several executive level roles at the Pharmacia Corporation, The Upjohn Company and Pfizer.

Mr. Agos earned his bachelor of science in biology from Rider University and The Upjohn Company Executive Masters from Thunderbird University. He is a Member of the Grandon Society with the Thomas Jefferson University College of Population Health. He is also a member of the Board Leadership Council of the New Jersey Health Care Quality Institute and The Compassionate Care Foundation of New Jersey.

About the American Diabetes Association

Nearly half of American adults have diabetes or prediabetes; more than 30 million adults and children have diabetes; and every 21 seconds, another individual is diagnosed with diabetes in the U.S. Founded in 1940, the American Diabetes Association (ADA) is the nation’s leading voluntary health organization whose mission is to prevent and cure diabetes, and to improve the lives of all people affected by diabetes. The ADA drives discovery by funding research to treat, manage and prevent all types of diabetes, as well as to search for cures; raises voice to the urgency of the diabetes epidemic; and works to safeguard policies and programs that protect people with diabetes. In addition, the ADA supports people living with diabetes, those at risk of developing diabetes, and the health care professionals who serve them through information and programs that can improve health outcomes and quality of life. For more information, please call the ADA at 1-800-DIABETES (1-800-342-2383) or visit diabetes.org. Information from both of these sources is available in English and Spanish. Find us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn)